Cargando…
Retracted: Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification
Autor principal: | and Alternative Medicine, Evidence-Based Complementary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567180/ https://www.ncbi.nlm.nih.gov/pubmed/37829632 http://dx.doi.org/10.1155/2023/9782478 |
Ejemplares similares
-
Retracted: Identification of Prognostic LncRNAs Subtypes Predicts Prognosis and Immune Microenvironment for Glioma
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
Retracted: Characterization of lncRNA-Based ceRNA Network and Potential Prognostic Hub Genes for Sepsis
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
Retracted: Changes and Prognostic Value of lncRNA CASC9 in Patients with Advanced Colon Cancer after Chemotherapy
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
Retracted: Knockdown of lncRNA HOXD-AS2 Improves the Prognosis of Glioma Patients by Inhibiting the Proliferation and Migration of Glioma Cells
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
Retracted: Influence of LncRNA NKILA on Bloodstream Infection of Hypervirulent Klebsiella pneumoniae and Its Ability to Induce Delayed Neutrophil Apoptosis
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)